Organon & Co. Share Price Today
(NASDAQ: OGN)

Name: Organon & Co. Share Price Today (NASDAQ: OGN) - Organon & Co. Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Organon & Co. share price is $15.56 & ₹1,348.12 as on 1 Feb 2025, 2.30 'hrs' IST

$15.56

▲

-0.41

(-2.57%)

Market is closed - opens 8 PM, 03 Feb 2025

View live Organon & Co. share price in Dollar and Rupees. Guide to invest in Organon & Co. stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Organon & Co., along with analyst recommendations, forecasts, and comprehensive financials.

Organon & Co. share price movements

Today's Low: $15.56
Today's High: $15.93
$15.56
0.0%
Downside
Day's Volatility :2.32%
Upside
2.32%
52 Weeks Low: $13.87
52 Weeks High: $23.10
$15.56
10.86%
Downside
52 Weeks Volatility :39.96%
Upside
32.64%

Organon & Co. (OGN) Returns

Period	Organon & Co.	Sector (Health Care)	Index (Russel 2000)
3 Months	-8.04%	-0.6%	0.0%
6 Months	-22.93%	-2.8%	0.0%
1 Year	-6.49%	3.3%	0.0%
3 Years	-53.32%	11.6%	-13.7%

Organon & Co. (OGN) Key Statistics

in dollars & INR

Previous Close	$15.97
Open	$15.9
Today's High	$15.93
Today's Low	$15.56
Market Capitalization	$4.1B
Today's Volume	$2.7M
52 Week High	$23.1
52 Week Low	$13.87
Revenue TTM	$6.4B
EBITDA	$1.8B
Earnings Per Share (EPS)	$5.05
PE Ratio	3.16
Dividend Yield	7.01%
Profit Margin	20.3%
Quarterly Earnings Growth YOY	5.08%
Return On Equity TTM	0.0%

How to invest in Organon & Co. Stock (OGN) from India?

It is very easy for Indian residents to invest directly in Organon & Co. from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Organon & Co. stock in both Indian Rupees (INR) and US Dollars (USD). Search for Organon & Co. or OGN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Organon & Co. or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Organon & Co. shares which would translate to 0.056 fractional shares of Organon & Co. as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Organon & Co., in just a few clicks!

Returns in Organon & Co. (OGN) for Indian investors in Rupees

The Organon & Co. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Organon & Co. investment value today

Current value as on today

₹98,069

Returns

₹1,931

(-1.93%)

Returns from Organon & Co. Stock

₹6,490 (-6.49%)

Dollar Returns

₹4,559 (+4.56%)

Indian investors sentiment towards Organon & Co. (OGN)

-19%

Period: Jan 1, 2025 to Jan 31, 2025. Change in 30 Days versus previous period

Search interest for Organon & Co. Stock from India on INDmoney has decreased by -19% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Organon & Co.

BlackRock Inc
12.48%
Vanguard Group Inc
11.72%
Massachusetts Financial Services Company
3.79%
State Street Corp
3.49%
LSV Asset Management
2.91%
Nordea Investment Mgmt Bank Demark A/s
2.62%

Analyst Recommendation on Organon & Co.

Buy

50%Buy

42%Hold

7%Sell

Based on 14 Wall street analysts offering stock ratings for Organon & Co.(by analysts ranked 0 to 5 stars)

Based on 14 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Organon & Co. Stock (OGN)

What analysts predicted

Upside of 34.96%

Target:

$21.00

Current:

$15.56

Insights on Organon & Co. Stock (Ticker Symbol: OGN)

Price Movement
In the last 6 months, OGN stock has moved down by -28.1%
Decreasing Revenue
Revenue is down for the last 3 quarters, 1.62B → 1.58B (in $), with an average decrease of 1.2% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 195.0M → 359.0M (in $), with an average increase of 45.7% per quarter
OGN vs LLY (1 yr)
In the last 1 year, Eli Lilly And Company has given 22.8% return, outperforming this stock by 32.5%
OGN vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 226.7% return, outperforming this stock by 279.5%
Price to Sales
ForOGN every $1 of sales, investors are willing to pay $0.6, whereas for Eli Lilly And Company, the investors are paying $17.9 for every $1 of sales.

OGN Organon & Co. Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$9.8B	↓ 6.89%
Net Income	$2.2B	↑ 19.54%
Net Profit Margin	22.02%	↑ 4.87%

	FY19	Y/Y Change
Revenue	$7.8B	↓ 20.46%
Net Income	$3.2B	↑ 49.47%
Net Profit Margin	41.38%	↑ 19.36%

	FY20	Y/Y Change
Revenue	$8.1B	↑ 4.1%
Net Income	$2.2B	↓ 32.88%
Net Profit Margin	26.68%	↓ 14.7%

	FY21	Y/Y Change
Revenue	$6.3B	↓ 22.13%
Net Income	$1.4B	↓ 37.45%
Net Profit Margin	21.43%	↓ 5.25%

	FY22	Y/Y Change
Revenue	$6.2B	↓ 2.06%
Net Income	$917.0M	↓ 32.12%
Net Profit Margin	14.85%	↓ 6.58%

	FY23	Y/Y Change
Revenue	$6.3B	↑ 1.44%
Net Income	$1.0B	↑ 11.56%
Net Profit Margin	16.33%	↑ 1.48%

	Q2 FY23	Q/Q Change
Revenue	$1.6B	↑ 4.55%
Net Income	$242.0M	↑ 36.72%
Net Profit Margin	15.05%	↑ 3.54%

	Q3 FY23	Q/Q Change
Revenue	$1.5B	↓ 5.53%
Net Income	$58.0M	↓ 76.03%
Net Profit Margin	3.82%	↓ 11.23%

	Q4 FY23	Q/Q Change
Revenue	$1.6B	↑ 5.2%
Net Income	$546.0M	↑ 841.38%
Net Profit Margin	34.17%	↑ 30.35%

	Q1 FY24	Q/Q Change
Revenue	$1.6B	↑ 1.5%
Net Income	$201.0M	↓ 63.19%
Net Profit Margin	12.39%	↓ 21.78%

	Q2 FY24	Q/Q Change
Revenue	$1.6B	↓ 0.92%
Net Income	$195.0M	↓ 2.99%
Net Profit Margin	12.13%	↓ 0.26%

	Q3 FY24	Q/Q Change
Revenue	$1.6B	↓ 1.56%
Net Income	$359.0M	↑ 84.1%
Net Profit Margin	22.69%	↑ 10.56%

	FY18	Y/Y Change
Profit	$5.1B	↓ 12.99%

	FY19	Y/Y Change
Profit	$5.5B	↑ 8.24%

	FY20	Y/Y Change
Profit	$4.7B	↓ 13.7%

	FY21	Y/Y Change
Profit	$3.9B	↓ 17.41%

	FY22	Y/Y Change
Profit	$3.9B	↓ 1.07%

	FY23	Y/Y Change
Profit	$3.7B	↓ 3.4%

	Q2 FY23	Q/Q Change
Profit	$968.0M	↑ 1.04%

	Q3 FY23	Q/Q Change
Profit	$907.0M	↓ 6.3%

	Q4 FY23	Q/Q Change
Profit	$915.0M	↑ 0.88%

	Q1 FY24	Q/Q Change
Profit	$957.0M	↑ 4.59%

	Q2 FY24	Q/Q Change
Profit	$939.0M	↓ 1.88%

	Q3 FY24	Q/Q Change
Profit	$923.0M	↓ 1.7%

	FY18	Y/Y Change
Operating Cash Flow	$3.7B	↑ 7.84%
Investing Cash Flow	$-69.0M	↑ 23.21%
Financing Cash Flow	$-4.2B	↑ 23.49%

	FY19	Y/Y Change
Operating Cash Flow	$2.8B	↓ 24.95%
Investing Cash Flow	$-102.0M	↑ 47.83%
Financing Cash Flow	$-2.6B	↓ 37.06%

	FY20	Y/Y Change
Operating Cash Flow	$2.2B	↓ 20.96%
Investing Cash Flow	$-258.0M	↑ 152.94%
Financing Cash Flow	$-2.2B	↓ 17.02%

	FY21	Y/Y Change
Operating Cash Flow	$2.5B	↑ 12.39%
Investing Cash Flow	$-481.0M	↑ 86.43%
Financing Cash Flow	$-1.3B	↓ 38.71%

	FY22	Y/Y Change
Operating Cash Flow	$858.0M	↓ 65.09%
Investing Cash Flow	$-420.0M	↓ 12.68%
Financing Cash Flow	$-433.0M	↓ 67.52%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$27.0M	↓ 76.32%
Investing Cash Flow	$-70.0M	↑ 29.63%
Financing Cash Flow	$-88.0M	↓ 73.01%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$261.0M	↑ 866.67%
Investing Cash Flow	$-179.0M	↑ 155.71%
Financing Cash Flow	$-78.0M	↓ 11.36%

Organon & Co. Technicals Summary

Sell

Neutral

Buy

Organon & Co. is currently in a neutral trading position according to technical analysis indicators.

Organon & Co. (OGN) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Organon & Co.	4.01%	-22.93%	-6.49%	-53.32%	-56.78%
Eli Lilly And Company	4.24%	4.62%	21.48%	223.36%	475.23%
Johnson & Johnson	5.65%	-5.64%	-2.85%	-11.93%	1.32%
Merck & Co. Inc.	-0.35%	-12.01%	-21.83%	20.5%	13.14%
Novo Nordisk A/s	-3.51%	-32.98%	-25.73%	58.46%	177.07%
Abbvie Inc	2.49%	-0.25%	9.03%	32.66%	123.45%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Organon & Co.	3.16	3.16	NA	4.11	0.0	0.08	0.07	1.91
Eli Lilly And Company	87.21	87.21	0.77	12.88	0.65	0.14	0.01	15.83
Johnson & Johnson	26.11	26.11	0.96	10.55	0.21	0.08	0.03	29.14
Merck & Co. Inc.	20.56	20.56	0.07	7.65	0.28	0.11	0.03	17.58
Novo Nordisk A/s	28.83	28.83	1.42	22.15	0.89	0.21	0.02	27.07
Abbvie Inc	61.42	61.42	0.41	10.39	0.56	0.08	0.04	3.41

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Organon & Co.	Buy	$4.1B	-56.78%	3.16	20.3%
Eli Lilly And Company	Buy	$729.4B	475.23%	87.21	20.48%
Johnson & Johnson	Buy	$363.9B	1.32%	26.11	16.74%
Merck & Co. Inc.	Buy	$248.6B	13.14%	20.56	19.23%
Novo Nordisk A/s	Buy	$377.0B	177.07%	28.83	35.01%
Abbvie Inc	Buy	$310.4B	123.45%	61.42	9.22%

Organon & Co. Dividend announcements

Organon & Co. Dividends December, 2024
In the quarter ending December,2024. Organon & Co. has declared dividend of $0.28
Read More

About Organon & Co.

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

Organization	Organon & Co.
Employees	10000
CEO	Mr. Kevin Ali
Industry	Healthcare

Management People of Organon & Co.

Name	Title
Mr. Kevin Ali	CEO & Director
Mr. Matthew M. Walsh C.F.A.	Executive VP & CFO
Mr. Kirke Weaver	Executive VP, General Counsel & Corporate Secretary

Important FAQs about investing in OGN Stock from India :

What is Organon & Co. share price today?

Organon & Co. share price today stands at $15.56, Open: $15.90 ; Previous Close: $15.97 ; High: $15.93 ; Low: $15.56 ; 52 Week High: $23.10 ; 52 Week Low: $13.87.

The stock opens at $15.90, after a previous close of $15.97. The stock reached a daily high of $15.93 and a low of $15.56, with a 52-week high of $23.10 and a 52-week low of $13.87.

Can Indians buy Organon & Co. shares?

Yes, Indians can invest in the Organon & Co. (OGN) from India.

With INDmoney, you can buy Organon & Co. at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Organon & Co. at zero transaction cost.

How can I buy Organon & Co. shares from India?

It is very easy to buy Organon & Co. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Organon & Co. (OGN) be purchased?

Yes, you can buy fractional shares of Organon & Co. with INDmoney app.

What are the documents required to start investing in Organon & Co. stocks?

To start investing in Organon & Co., You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.